$APVO News

Last published 20h ago

20h agoAPVOAptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross ProceedsACCESS NewswireAptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced that the Company has entered into warrant inducement letter agreements with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have agreed to exercise in full fo ...
2d agoAPVOAptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid TumorsACCESS NewswireAptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel bispecific and multispecific immunotherapies for the treatment of cancer, today announced that on November 7, 2026, the Company presented new preclinical data from its next-generation multispecific platform at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. The findings de ...
6d agoAPVOAptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AMLACCESS NewswireRefined priming-dose regimen addresses important treatment-tolerability objective identified through FDA discussions, further strengthening mipletamig's readiness for Phase 2 developmentSubstantial reduction in
2w agoAPVOAptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell TransplantACCESS NewswireTen patients initially deemed unfit for intensive chemotherapy proceeded to stem cell transplantTransplant rate compares favorably with historical standard-of-care experience, adding to growing clinical evidence
4w agoAPVOAptevo to Showcase Multispecific Platform at SITC 2026 Annual MeetingACCESS NewswireNext generation multispecific technology designed to coordinate innate and adaptive immune activity within the tumor microenvironment SEATTLE, WA / ACCESS Newswire / October 14, 2026 / Aptevo Therapeutics Inc.
1mo agoAPVOAptevo Advances Next-Generation Trispecific Candidate Toward Clinical DevelopmentACCESS NewswireCompany Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human TestingTrispecifics Combine Three Complementary Cancer-Fighting Functions in One Molecule,
2mo agoAPVOAptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AMLACCESS NewswireRemission results nearly double published ven/aza outcomes in patients with historically limited treatment success SEATTLE, WA / ACCESS Newswire / September 3, 2026 / Aptevo Therapeutics Inc. , a
2mo agoAPVOAptevo Provides 2Q26 Business Update and Reports Second Quarter Financial ResultsACCESS NewswireMipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology PipelineNon-Dilutive Grant Funding Advances
3mo agoAPVOAptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross ProceedsACCESS NewswireSEATTLE, WA / ACCESS Newswire / August 13, 2026 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company developing novel multispecific immuno-oncology
3mo agoAPVOAptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross ProceedsACCESS NewswireSEATTLE, WA / ACCESS Newswire / August 12, 2026 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company developing novel multispecific immuno-oncology
3mo agoAPVOAptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting BackboneACCESS NewswireFiling supports potential development of radiopharmaceuticals, T-cell engagers and other immune-based approaches using a versatile platform approach SEATTLE, WA / ACCESS Newswire / July 27, 2026 / Aptevo Therapeutics
4mo agoAPVOAptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid TumorsACCESS NewswireSEATTLE, WA / ACCESS Newswire / June 30, 2026 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and
5mo agoAPVOAptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific OfficerACCESS NewswireExperienced oncology R&D leader appointed to support Aptevo's expanding oncology pipeline and new radiopharmaceutical development strategy SEATTLE, WA / ACCESS Newswire / May 28, 2026 / Aptevo Therapeutics Inc.
5mo agoAPVOAptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at ClosingACCESS Newswire50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical ProgramsInnovation and Investment Continue to Accelerate Across Radiopharmaceutical Oncology SEATTLE, WA AND LANSING, MI / ACCESS Newswire / May
6mo agoAPVOAptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose SelectionACCESS NewswireMipletamig continues to perform, delivers 87% clinical benefit and 81% remission in frontline AML, with no CRS in frontline patientsExecutive leadership transition complete. Jeff Lamothe appointed CEO; Marvin White
6mo agoAPVOAptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose SelectionACCESS NewswireProgram Enters Final Stage of Dose OptimizationData Continue to Demonstrate Strong Clinical Activity and Favorable Safety Across an Expanding Frontline Dataset SEATTLE, WA / ACCESS Newswire / May 6, 2026 / Aptevo
7mo agoAPVOAptevo Provides State of the Business Report and 2025 Financial ResultsACCESS NewswireLatest mipletamig data delivers 86% clinical benefit rate with no cytokine release syndrome in 28 frontline AML patients, supporting its potential to enhance standard-of-care combination therapyCompany expands CD3
7mo agoAPVOAptevo to Participate in March 2026 ConferencesACCESS NewswireSEATTLE, WA / ACCESS Newswire / March 19, 2026 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and
8mo agoAPVOMipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%ACCESS NewswireFrontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidineSEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo Therapeutics Inc. ,
9mo agoAPVOAptevo Announces Executive Leadership Transitions to Support Next Phase of GrowthACCESS NewswireClinical progress, pipeline expansion, and operational momentum underpin leadership continuity as the Company advances into 2026 and beyondSEATTLE, WA / ACCESS Newswire / February 3, 2026 / Aptevo Therapeutics Inc.
10mo agoAPVOAptevo Therapeutics Announces 1-for-18 Reverse Stock SplitACCESS NewswireSEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary
11mo agoAPVOAptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025ACCESS Newswire100% of patients in Cohorts 1-3 remain free of cytokine release syndromeCRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability with standard of care
1y agoAPVOAptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid TumorsACCESS NewswireFirst data on Aptevo's new molecule presented at the Society for Immunotherapy of Cancer Annual Meeting SEATTLE, WASHINGTON / ACCESS Newswire / November 10, 2025 / Aptevo Therapeutics ("Aptevo" or the
1y agoAPVOAptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business UpdateACCESS Newswire89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trialsIntroduces first trispecific molecules, APVO451 and APVO452, advancing therapies designed to overcome
1y agoAPVOMipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AMLACCESS NewswireNo dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable safety and tolerabilityTrial progressing efficiently, Cohort 4 open for enrollment SEATTLE, WA
1y agoAPVOAptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five MoleculesACCESS NewswireNew candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and immunosuppressive
1y agoAPVOAptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate CancerACCESS NewswireBuilds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS-7-derived CD3
1y agoAPVOAptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business UpdateACCESS NewswireMipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor typesCD3 bispecific
1y agoAPVOAptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq RulesACCESS NewswireSEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary
1y agoAPVOAptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell EngagersACCESS NewswireMipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumorsNew candidate APVO455 targets Nectin-4+ cancers, joins mipletamig and
1y agoAPVOAptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq RulesACCESS NewswireSEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary
1y agoAPVOMipletamig Demonstrates Compelling Clinical Activity in Frontline AMLACCESS Newswire85% remission rate observed in evaluable frontline AML patientsMipletamig combination enables rare pathway to transplant in a previously ineligible unfit patientNo dose-limiting toxicities observed among evaluable
1y agoAPVOAptevo Participating in the BIO International ConventionACCESS NewswireSEATTLE, WA / ACCESS Newswire / June 13, 2025 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary
1y agoAPVOAptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance PlanACCESS NewswireSEATTLE, WA / ACCESS Newswire / May 22, 2025 / Aptevo Therapeutics Inc. , today announced that it will conduct a reverse stock split of its outstanding shares
1y agoAPVOAptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on MipletamigACCESS Newswire9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trialsMipletamig triplet combination continues to outperform standard doublet benchmarkNo cytokine release syndrome observed
1y agoAPVOAptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune ActivationACCESS NewswireAs lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR® platformIn preclinical studies, APVO711
1y agoAPVOAptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesACCESS NewswireSEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel immune-oncology
1y agoAPVOAptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesACCESS NewswireSEATTLE, WASHINGTON / ACCESS Newswire / April 21, 2025 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel
1y agoAPVOAptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesACCESS NewswireSEATTLE, WASHINGTON / ACCESS Newswire / April 4, 2025 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel
1y agoAPVOAptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesACCESS NewswireSEATTLE, WA / ACCESS Newswire / April 3, 2025 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel immune-oncology
1y agoAPVORAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of TreatmentACCESS NewswireAcross two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of careTriplet Combination with mipletamig continues to outperform doublet combination
1y agoAPVOAptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor ImmunotherapyACCESS NewswireContinues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics , a leader in the
1y agoAPVOAptevo to Participate in March ConferencesACCESS NewswireSEATTLE, WA / ACCESS Newswire / March 6, 2025 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary
1y agoAPVOAptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVACCESS NewswireMarvin White, President and CEO, Talks Clinical Progress, Innovation and Long-Term Growth ORLANDO, FL / ACCESS Newswire / February 15, 2025 / RedChip Companies announced today that an interview with Aptevo Therapeutics'
1y agoAPVOAptevo Therapeutics Reports 2024 Financial Results And Provides A Business UpdateACCESS Newswire100% of Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment ContinuesPromising Data, including a 59% Stable Disease Rate,
1y agoAPVOAptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025ACCESS NewswireAlso giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering and rational drug design expertise
1y agoAPVOAptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross ProceedsACCESS NewswireSEATTLE, WASHINGTON / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel
1y agoAPVO100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML TrialACCESS NewswireTwo of three patients achieved both complete remission and MRD-negative statusHigh response rates observed in earlier studies continue in ongoing mipletamig trialCohort 2 enrollment commencing SEATTLE, WA / ACCESSWIRE /
1y agoAPVOBispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side EffectsACCESS NewswirePowered by Aptevo's proprietary ADAPTIR-FLEX®platform, antibody innovation targeting difficult-to-treat cancers SEATTLE, WA / ACCESSWIRE / December 4, 2024 / Aptevo Therapeutics Inc. , a clinical-stage
1y agoAPVOAptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance PlanACCESS NewswireSEATTLE, WA / ACCESSWIRE / November 29, 2024 / Aptevo Therapeutics Inc. , today announced that it will conduct a reverse stock split of its outstanding shares